These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16897320)

  • 1. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.
    Pal A; Glekas A; Doubrovin M; Balatoni J; Namavari M; Beresten T; Maxwell D; Soghomonyan S; Shavrin A; Ageyeva L; Finn R; Larson SM; Bornmann W; Gelovani JG
    Mol Imaging Biol; 2006; 8(5):262-77. PubMed ID: 16897320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with [(124)i]-morpholino-IPQA.
    Yeh SH; Lin CF; Kong FL; Wang HE; Hsieh YJ; Gelovani JG; Liu RS
    Biomed Res Int; 2013; 2013():549359. PubMed ID: 23956990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT.
    Yeh HH; Ogawa K; Balatoni J; Mukhapadhyay U; Pal A; Gonzalez-Lepera C; Shavrin A; Soghomonyan S; Flores L; Young D; Volgin AY; Najjar AM; Krasnykh V; Tong W; Alauddin MM; Gelovani JG
    Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1603-8. PubMed ID: 21220318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiosynthesis and initial in vitro evaluation of [18F]F-PEG6-IPQA--a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas.
    Pal A; Balatoni JA; Mukhopadhyay U; Ogawa K; Gonzalez-Lepera C; Shavrin A; Volgin A; Tong W; Alauddin MM; Gelovani JG
    Mol Imaging Biol; 2011 Oct; 13(5):853-61. PubMed ID: 20859697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system.
    Medina OP; Pillarsetty N; Glekas A; Punzalan B; Longo V; Gönen M; Zanzonico P; Smith-Jones P; Larson SM
    J Control Release; 2011 Feb; 149(3):292-8. PubMed ID: 21047536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.
    Pantaleo MA; Mishani E; Nanni C; Landuzzi L; Boschi S; Nicoletti G; Dissoki S; Paterini P; Piccaluga PP; Lodi F; Lollini PL; Fanti S; Biasco G
    Mol Imaging Biol; 2010 Dec; 12(6):616-25. PubMed ID: 20379787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer.
    Pantaleo MA; Nannini M; Maleddu A; Fanti S; Nanni C; Boschi S; Lodi F; Nicoletti G; Landuzzi L; Lollini PL; Biasco G
    Ann Oncol; 2009 Feb; 20(2):213-26. PubMed ID: 18842614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
    Li D; Zou S; Cheng S; Song S; Wang P; Zhu X
    Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CAIX with [
    Yang X; Zhu H; Yang X; Li N; Huang H; Liu T; Guo X; Xu X; Xia L; Deng C; Tian X; Yang Z
    Mol Pharm; 2019 Apr; 16(4):1532-1540. PubMed ID: 30803240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.
    Pool M; Kol A; Lub-de Hooge MN; Gerdes CA; de Jong S; de Vries EG; Terwisscha van Scheltinga AG
    Oncotarget; 2016 Oct; 7(42):68111-68121. PubMed ID: 27602494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET imaging of EGFR expression using an
    Cheng S; Jacobson O; Zhu G; Chen Z; Liang SH; Tian R; Yang Z; Niu G; Zhu X; Chen X
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):948-956. PubMed ID: 30069577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
    Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
    Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain.
    Petrulli JR; Sullivan JM; Zheng MQ; Bennett DC; Charest J; Huang Y; Morris ED; Contessa JN
    Neoplasia; 2013 Dec; 15(12):1347-53. PubMed ID: 24403856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body biodistribution kinetics, metabolism, and radiation dosimetry estimates of 18F-PEG6-IPQA in nonhuman primates.
    Tian M; Ogawa K; Wendt R; Mukhopadhyay U; Balatoni J; Fukumitsu N; Uthamanthil R; Borne A; Brammer D; Jackson J; Mawlawi O; Yang B; Alauddin MM; Gelovani JG
    J Nucl Med; 2011 Jun; 52(6):934-41. PubMed ID: 21571803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
    Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
    Int J Oncol; 2019 Apr; 54(4):1209-1220. PubMed ID: 30968147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor.
    Chang AJ; De Silva RA; Lapi SE
    Mol Imaging; 2013; 12(1):17-27. PubMed ID: 23348788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents.
    Neto C; Fernandes C; Oliveira MC; Gano L; Mendes F; Kniess T; Santos I
    Nucl Med Biol; 2012 Feb; 39(2):247-60. PubMed ID: 22079040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.
    Yamaguchi A; Achmad A; Hanaoka H; Heryanto YD; Bhattarai A; Ratianto ; Khongorzul E; Shintawati R; Kartamihardja AAP; Kanai A; Sugo Y; S Ishioka N; Higuchi T; Tsushima Y
    BMC Cancer; 2019 Oct; 19(1):1000. PubMed ID: 31651282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
    Heimberger AB; Learn CA; Archer GE; McLendon RE; Chewning TA; Tuck FL; Pracyk JB; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2002 Nov; 8(11):3496-502. PubMed ID: 12429640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET of EGFR expression with an 18F-labeled affibody molecule.
    Miao Z; Ren G; Liu H; Qi S; Wu S; Cheng Z
    J Nucl Med; 2012 Jul; 53(7):1110-8. PubMed ID: 22689926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.